Table 3.
AEs and events which caused therapeutic modifications of Atezo/Bev during time to progression (n = 100).
| Grade of AEs | Therapeutic Modification of Both Atezo and Bev |
Therapeutic Modification of Bev | |||||
|---|---|---|---|---|---|---|---|
| Any | ≥3 | Interruption | Discontinuation | Reduction | Interruption | Discontinuation | |
| Immune-related AEs | |||||||
| Rash | 12 | 0 | 0 | 1 | 0 | 0 | 0 |
| Hypothyroidism | 6 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperthyroidism | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Infusion-related reaction | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pneumonitis | 3 | 1 | 1 | 2 | 0 | 0 | 0 |
| Hepatitis | 3 | 2 | 1 | 2 | 0 | 0 | 0 |
| Adrenal insufficiency | 2 | 0 | 0 | 1 | 0 | 0 | 0 |
| Hypopituitarism | 2 | 1 | 0 | 1 | 0 | 0 | 0 |
| Colitis | 1 | 1 | 2 | 0 | 0 | 0 | 0 |
| Myositis | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Sjögren syndrome | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| AEs other than immune-related AEs | |||||||
| Increase in AST | 48 | 2 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia | 47 | 1 | 2 | 2 | 0 | 0 | 0 |
| Hypertension | 41 | 9 | 0 | 0 | 0 | 0 | 1 |
| Proteinuria | 40 | 7 | 2 | 0 | 4 | 8 | 6 |
| Fatigue | 38 | 1 | 2 | 2 | 0 | 0 | 0 |
| Decrease in platelet count | 34 | 3 | 1 | 1 | 0 | 0 | 0 |
| Increase in ALT | 28 | 1 | 0 | 0 | 0 | 0 | 0 |
| Anemia | 23 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pruritis | 23 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anorexia | 22 | 1 | 1 | 0 | 3 | 1 | 0 |
| Bleeding or hemorrhage | 19 | 4 | 2 | 0 | 1 | 1 | 0 |
| Ascites | 18 | 1 | 3 | 3 | 1 | 0 | 1 |
| Fever | 16 | 0 | 1 | 2 | 1 | 0 | 0 |
| Decrease in white blood cells | 15 | 5 | 0 | 0 | 0 | 0 | 0 |
| Weight loss | 14 | 0 | 0 | 0 | 0 | 0 | 0 |
| Increase in blood bilirubin | 12 | 0 | 0 | 3 | 1 | 0 | 0 |
| Edema limbs | 10 | 0 | 0 | 1 | 1 | 2 | 1 |
| Diarrhea | 9 | 0 | 0 | 0 | 0 | 0 | 0 |
| Increase in creatinine | 8 | 0 | 0 | 0 | 0 | 0 | 0 |
| Decrease in neutrophil count | 7 | 2 | 0 | 0 | 0 | 0 | 0 |
| Nausea | 5 | 1 | 0 | 0 | 0 | 0 | 0 |
| Infection | 5 | 4 | 4 | 0 | 0 | 1 | 0 |
| Palmar-plantar erythrodysesthesia syndrome | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Encephalopathy | 3 | 3 | 0 | 2 | 0 | 0 | 0 |
| Congestive heart failure | 2 | 1 | 1 | 1 | 0 | 0 | 0 |
| Thromboembolic event | 2 | 1 | 0 | 2 | 0 | 0 | 0 |
| Wound dehiscence | 1 | 0 | 0 | 0 | 0 | 1 | 0 |
| Invasive therapy associated with risk of wound healing complications during the administration of Bev | |||||||
| Implantation of a CV access port | - | - | 7 | 0 | 0 | 1 | 0 |
| Operation for bone fracture | - | - | 1 | 0 | 0 | 2 | 0 |
| Therapies for the prevention of esophageal varix rupture | - | - | 1 | 0 | 0 | 1 | 0 |
Adverse events were evaluated based on the Common Terminology Criteria for Adverse Events version 5.0. Variables are expressed as the total number. Abbreviations: AEs, adverse events; AST, aspartate aminotransferase; Atezo/Bev, atezolizumab plus bevacizumab therapy; ALT, alanine aminotransferase; Atezo, atezolizumab; Bev, bevacizumab; CV, central venous.